Skip navigation

Proactive Strategies for Managing Risks in Patient Support Services, Specialty Pharmacy Contracting and Government Price Reporting

September 13-14, 2018
  • Boston, MA

CBI’s Compliance Congress for Specialty Products serves as the life sciences industry’s only conference catered to the unique compliance challenges for specialty bio/pharmaceutical companies, pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for manufacturers. A comprehensive compliance program is essential to correctly assessing risks, including patient assistance programs, non-commercial activities, third-party relationships and pharmacy contracting. At this fourth annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Benchmark with Your Peers and Explore
the Top Risk Hot Spots for 2018:

  • Assess risk exposure associated with Patient Assistance Programs and Patient Support Services
  • Break down the essentials for an effective compliance program pre- and post-commercialization
  • Hear about the high-priority risk areas for biotech and specialty pharma from government agencies, including DOJ
  • Examine core pharmacy services v. enhanced pharmacy services and how to determine what is essential for your organization
  • Review current and pending state transparency and disclosure legislation
  • Share proactive approaches to managing emerging risk areas at the 2020 Specialty Café
  • Understand GDPR and discuss why it matters to U.S. companies of all sizes

Meet Our Boston Advisory Board:

Daryl Kreml
Chief Compliance Officer, VP
SAGE Therapeutics

Heather Golding
Vice President,
Head of Legal & Compliance
Sobi, Inc.

Jerald Korn
Vice President, Assistant General Counsel, Chief Compliance Officer
TESARO, Inc.

Paul Ham
Executive Director, Corporate Compliance (North America)
Bioverativ

Andrea Kocharyan
Vice President, Legal Affairs
Boston BioMedical

Katherine Chaurette
Senior Director, Assistant General Counsel
Regeneron

Previous Attendee Acclaim:

This is the only conference that I am aware of that
focuses on compliance for specialty products. The
unique forum provides a great opportunity to share
best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

This is a phenomenal program, with insightful and real-world examples and solutions for managing risk.

Anonymous

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

Compliance Congress for Specialty Products

Proactive Strategies for Managing Risks in Patient Support Services, Specialty Pharmacy Contracting and Government Price Reporting

CBI’s Compliance Congress for Specialty Products serves as the life sciences industry’s only conference catered to the unique compliance challenges for specialty bio/pharmaceutical companies, pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for manufacturers. A comprehensive compliance program is essential to correctly assessing risks, including patient assistance programs, non-commercial activities, third-party relationships and pharmacy contracting. At this fourth annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Benchmark with Your Peers and Explore
the Top Risk Hot Spots for 2018:

  • Assess risk exposure associated with Patient Assistance Programs and Patient Support Services
  • Break down the essentials for an effective compliance program pre- and post-commercialization
  • Hear about the high-priority risk areas for biotech and specialty pharma from government agencies, including DOJ
  • Examine core pharmacy services v. enhanced pharmacy services and how to determine what is essential for your organization
  • Review current and pending state transparency and disclosure legislation
  • Share proactive approaches to managing emerging risk areas at the 2020 Specialty Café
  • Understand GDPR and discuss why it matters to U.S. companies of all sizes

Meet Our Boston Advisory Board:

Daryl Kreml
Chief Compliance Officer, VP
SAGE Therapeutics

Heather Golding
Vice President,
Head of Legal & Compliance
Sobi, Inc.

Jerald Korn
Vice President, Assistant General Counsel, Chief Compliance Officer
TESARO, Inc.

Paul Ham
Executive Director, Corporate Compliance (North America)
Bioverativ

Andrea Kocharyan
Vice President, Legal Affairs
Boston BioMedical

Katherine Chaurette
Senior Director, Assistant General Counsel
Regeneron

Previous Attendee Acclaim:

This is the only conference that I am aware of that
focuses on compliance for specialty products. The
unique forum provides a great opportunity to share
best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

This is a phenomenal program, with insightful and real-world examples and solutions for managing risk.

Anonymous

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics